Mirabegron Zentiva (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation relaxes the muscle during the storage phase, allowing the bladder to hold more urine and decreasing involuntary contractions that cause urgency and frequency.

The dosage of Mirabegron Zentiva is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Mirabegron during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Mirabegron Zentiva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Antimuscarinic drugs (e.g., oxybutynin) reduce bladder contractions by blocking muscarinic receptors, often causing dry‑mouth and constipation. Mirabegron works via a different β3‑adrenergic pathway and typically has a lower incidence of anticholinergic side effects, making it a useful alternative or add‑on therapy for patients who cannot tolerate antimuscarinics.

Store Mirabegron Zentiva at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mirabegron Zentiva is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water and do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events include acute urinary retention, severe hypertension, tachycardia, and rare allergic reactions such as angioedema. Patients experiencing difficulty urinating, a sudden rise in blood pressure, rapid heartbeat, or signs of an allergic response should seek immediate medical attention.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to Mirabegron or any excipients. Caution is also advised for individuals with significant renal dysfunction or those taking strong CYP2D6 inhibitors.